# A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

> **NCT05265325** · PHASE2 · COMPLETED · sponsor: **Kind Pharmaceuticals LLC** · enrollment: 175 (actual)

## Conditions studied

- Renal Anemia

## Interventions

- **DRUG:** AND017 capsules TIW
- **DRUG:** AND017 capsules QW
- **DRUG:** epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars

## Key facts

- **NCT ID:** NCT05265325
- **Lead sponsor:** Kind Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-03
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-04-25
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265325, "A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05265325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*